SCHEMBL30601628

SCHEMBL30601628

O=C1C=C(N2CCOCC2)c2ccccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 6/20 1.00
NPC1 O15118 5/20 1.00
TDP2 O95551 4/20 1.00
NSD2 O96028 4/20 1.00
KMT2A Q03164 4/20 1.00
HKDC1 Q2TB90 3/20 1.00
MEN1 O00255 3/20 1.00
RAB9A P51151 3/20 1.00
BLM P54132 2/20 1.00
GALK1 P51570 1/20 1.00
ATM Q13315 1/20 1.00
NOD2 Q9HC29 1/20 1.00
ATG4B Q9Y4P1 1/20 1.00
DNMT1 P26358 1/20 0.77
S100A4 P26447 2/20 0.61
MAPT P10636 10/20 0.54
HTT P42858 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
TP53 P04637 1/20 0.54
STAT3 P40763 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4647391 1.00 APAF1 (1.00) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL247037 0.88 KMT2A (0.79) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL7260223 0.83 APAF1 (1.00) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL4649553 0.80 DNMT1 (0.83) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL10037145 0.80 DNMT1 (0.77) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL10446509 0.77 TDP2 (0.73) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL14566962 0.76 KMT2A (0.61) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL9508287 0.76 MAPT (0.66) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL4649478 0.73 APAF1 (0.56) APAF1NPC1TDP2NSD2KMT2A
SCHEMBL4649480 0.73 APAF1 (0.56) APAF1NPC1TDP2NSD2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES Didenko, Kirill (US) 2025-07-03 US disclosed
CN-120091810-A Methods and highly bioavailable permeable compounds for treating viral diseases 基里尔·迪丹克 2025-06-03 CN disclosed
WO-2023187599-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES DIDENKO KIRILL (MX) 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES ACE2, FURIN, SARS1 APAF1 2334/4885NPC1 23/4885TDP2 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.